Point-of-Care i-STAT Cardiac Troponin I for Assessment of Patients with Symptoms Suggestive of Acute Coronary Syndrome,
- 1 February 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (2) , 322-325
- https://doi.org/10.1373/clinchem.2005.060293
Abstract
Background: Few studies have investigated the role of cardiac troponin point-of-care (POC) testing for predicting adverse outcomes in acute coronary syndrome (ACS) patients. We investigated the use of a POC cTnI assay in ACS patients. Methods: We studied consecutive patients (n = 367) presenting with symptoms suggestive of ACS who were admitted through the emergency department. We measured plasma cTnI with the i-STAT assay. Patients were risk-stratified based on cTnI concentrations defined by the predetermined 99th percentile reference limit for plasma (0.04 μg/L). Patients were followed for 60 days. We computed survival and event curves with the Kaplan–Meier method and compared risk stratification groups with the log-rank test. Results: Acute myocardial infarction (MI) was diagnosed in 8.1% of patients. Odds ratios and 95% confidence intervals for all-cause death (ACD), MI or ACD, MI or cardiac death, and cardiac death at 60 days were all statistically significant after adjustment for age, diabetes, hypertension, and history of renal failure as follows: 2.54 (1.24–5.20), P = 0.009; 2.76 (1.37–5.58), P = 0.003; 5.98 (1.65–21.7), P = 0.008; and 2.54 (1.24–5.20), P = 0.009. Kaplan–Meier curves showed early separation between patients with increased vs. reference concentrations before 30 days for ACD, MI or ACD, and MI or cardiac death. Conclusion: The i-STAT POC cTnI assay can be added to the list of assays for risk stratification.Keywords
This publication has 15 references indexed in Scilit:
- Validation of the 99th Percentile Cutoff Independent of Assay Imprecision (CV) for Cardiac Troponin Monitoring for Ruling Out Myocardial InfarctionClinical Chemistry, 2005
- Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range ConcentrationsClinical Chemistry, 2004
- European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trialsAmerican Heart Journal, 2002
- Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy)The American Journal of Cardiology, 2002
- Ability of Minor Elevations of Troponins I and T to Predict Benefit From an Early Invasive Strategy in Patients With Unstable Angina and Non-ST Elevation Myocardial InfarctionResults From a Randomized TrialJAMA, 2001
- Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudyJournal of the American College of Cardiology, 2001
- Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromesAmerican Heart Journal, 2000
- Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial InfarctionEuropean Heart Journal, 2000
- It’s Time for a Change to a Troponin StandardCirculation, 2000
- Emergency Room Triage of Patients with Acute Chest Pain by Means of Rapid Testing for Cardiac Troponin T or Troponin INew England Journal of Medicine, 1997